Taivex has announced that all three Phase I clinical projects, T-1101, T-1201, and T-1301, have been selected to present their project progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. At the conference, unveil for this is the first time to unveil relevant data including chemical structures, product characteristics, and clinical designs of …

Taivex Therapeutics attended the 2024 BIO-Europe SPRING conference in Barcelona, Spain (https://informaconnect.com/bioeurope-spring/) from March 18th to 20th. During the conference, Taivex engaged in discussions with several companies for internation collaborations, including global pharma, biotech, investors, etc., and will contact further afterward.

T-1301 Phase I clinical trial was initiated in Mid-December, 2021 in multiple centers in Taiwan. Getting through the tough 2022Q2 due to COVID-19 affected patient recruitment, the enrollment of the first patient (First-patient-in, FPI) was accomplished in August, 2022. Meanwhile, patient recruitment is ongoing. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. …

The discovery and development of our first-in-class Hec1/Nek2 inhibitor, oral anti-cancer drug T-1101 (Tosylate), have been accepted for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023).